368 related articles for article (PubMed ID: 34190962)
1. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
[TBL] [Abstract][Full Text] [Related]
2. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
[No Abstract] [Full Text] [Related]
3. Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
[TBL] [Abstract][Full Text] [Related]
4. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
[TBL] [Abstract][Full Text] [Related]
6. Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Clayton AH; Lasser R; Nandy I; Sankoh AJ; Jonas J; Kanes SJ
J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36811520
[No Abstract] [Full Text] [Related]
7. Trial of SAGE-217 in Patients with Major Depressive Disorder.
Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ
N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961
[TBL] [Abstract][Full Text] [Related]
8. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
Cutler AJ; Mattingly GW; Kornstein SG; Aaronson ST; Lasser R; Zhang H; Rana N; Brown C; Levin S; Miller C; Kotecha M; Forrestal F; Doherty J
J Clin Psychiatry; 2023 Dec; 85(1):. PubMed ID: 38153320
[No Abstract] [Full Text] [Related]
10. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
[TBL] [Abstract][Full Text] [Related]
11. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.
Kato M; Nakagome K; Baba T; Sonoyama T; Okutsu D; Yamanaka H; Shimizu R; Motomiya T; Inoue T
Psychiatry Clin Neurosci; 2023 Sep; 77(9):497-509. PubMed ID: 37252829
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J; Yang L; Yang G; Gao J
Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
[TBL] [Abstract][Full Text] [Related]
17. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
[TBL] [Abstract][Full Text] [Related]
18. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.
Epperson CN; Rubinow DR; Meltzer-Brody S; Deligiannidis KM; Riesenberg R; Krystal AD; Bankole K; Huang MY; Li H; Brown C; Kanes SJ; Lasser R
J Affect Disord; 2023 Jan; 320():353-359. PubMed ID: 36191643
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
Frieder A; Fersh M; Hainline R; Deligiannidis KM
CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
